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The in vitro and in vivo anti-tumor efficacy of methotrexate-loaded Fe3O4-poly-L-lactide-poly(ethylene glycol)-poly-L-lactide 
magnetic composite microspheres (MTX-Fe3O4-PLLA-PEG-PLLA MCMs, MMCMs), which were produced by co-precipita- 
tion (C) and microencapsulation (M) in a supercritical process, was evaluated at various levels: cellular, molecular, and inte-
grated. The results at the cellular level indicate that MMCMs (M) show a better anti-proliferation activity than raw MTX and 
could induce morphological changes of cells undergoing apoptosis. At the molecular level, MMCMs (M) lead to a significantly 
higher relative mRNA expression of bax/bcl-2 and caspase-3 than MMCMs (C) at 10 µg mL1 (P<0.01); and the pro-caspase-3 
protein expression measured by Western blot analysis also demonstrates that MMCMs (M) can effectively activate 
pro-caspase-3. At the integrated level, mice bearing a sarcoma-180 tumor are used; in vivo anti-tumor activity tests reveal that 
MMCMs (M) with magnetic induction display a much higher tumor suppression rate and lower toxicity than raw MTX. Phar-
macokinetic studies show that MMCMs (M) with magnetic induction significantly increase the accumulation of MTX in the 
tumor tissue compared with the other treatments. These results suggest that the MMCMs (M) prepared by the SpEDS process 
have great potential to play a positive role in the magnetic targeted therapy field.  
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Cancer is a leading cause of death worldwide, mainly be-
cause malignant tumor cells are highly genetically unstable 
and excessively proliferative, and they have an enhanced 
ability to invade cells and metastasize in comparison to 
normal cells [1]. In the treatment of several cancers, medi-
cal research has given considerable attention to increasing 
the local drug concentration around tumor tissue and mini-
mizing the systemic side-effects on normal tissues or cells. 
Recently, with the development and synergy of materials 
innovation and nanotechnology fuelling the therapy, various 
anticancer drug carriers have been advancement of drug 
delivery systems for cancer developed, such as polymer 
nanoparticles [2], nanoparticle suspensions [3], liposomes 
[4], dendritic macromolecules [5], inorganic nanoparticles 
[6], and functionalized carbon nanotubes [7]. Furthermore, 
in order to increase the targeting efficiency, increasing at-
tention has been given to targeted drug delivery systems 
(TDDS). The applications of the enhanced permeability and 
retention (EPR) effect [8], antibodies [9], folate [10], and 
cancer cell homing peptides [11] in TDDS have been re-
ported; the physicochemical methods represent another 
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promising way to achieve a targeted delivery by some stim-
ulus, such as temperature [12], pH [13], magnetic field [14], 
or mutual combination [15,16]. Among them, magnetic 
TDDS is used extensively to improve the targeting property 
by application of an external magnetic field; consequently, 
the therapeutic effects of drugs can be enhanced. 
As a new drug formulation candidate for biomedical ap-
plications, its safety and effectiveness must be evaluated 
before entering the clinical trials stage because of the poten-
tial alteration in the biological effects of the drug to be 
transported. Traditionally, the evaluation of the effective-
ness of a drug formulation has been focused on cell viability 
[17]. However, the evaluation at a cellular level is not com-
prehensive. For the sake of harvesting more reliable results, 
evaluating the effectiveness of the formulations at omnidi-
rectional levels is necessary [18,19]. At a cellular level, 
evaluation has mainly involved the detection of cell apopto-
sis by various methods with integrated advantages [20,21]. 
At a molecular level, the expressions of the apopto-
sis-related genes and proteins [22,23] have been the main 
focus of investigation. Evaluation at an integrated level has 
mainly examined anti-tumor activity and pharmacokinetics 
[24,25]. With the rapid development of life science and 
special features of formulations, some of the new evaluation 
methods should be adopted [26]. 
In our previous studies [27,28], using a process of 
SpEDS, MTX-Fe3O4-PLLA-PEG-PLLA magnetic compo-
site microspheres were produced by co-precipitation and 
microencapsulation processes [MMCMs (C/M)], and the 
biocompatibility of Fe3O4-PLLA-PEG-PLLA MCMs was 
evaluated. In this work, based on the above results, the ef-
fectiveness of MMCMs (C/M) was evaluated at three levels: 
cellular, molecular, and integrated. 
1  Materials and methods 
1.1  Materials and cell culture 
A schematic diagram of the SpEDS apparatus and the prep-
aration process was shown in our previous study [27]. In 
this work, theoretical drug loads were set at 10%, and the 
corresponding drug loads of MMCMs (C) and MMCMs (M) 
were 11.72%±0.00% and 5.06%±0.01%, respectively. 
These microspheres were further treated through cobalt-60 
radiation sterilization. 
Alamar blue was purchased from Invitrogen (USA). A 
normal/apoptotic/necrotic cell detection kit and a BCA pro-
tein estimation kit were purchased from Kaiji Bio-Company 
(Nanjing, China). A cell cycle and apoptosis analysis kit, 
cell lysis buffer for Western blot analysis and immunopre-
cipitation (IP), phenylmethylsulfonyl fluoride (PMSF), and 
BeyoECL Plus were purchased from the Beyotime Institute 
of Biotechnology (Jiangsu, China). The RNAiso Plus, Prime 
ScriptTM RT reagent kit and SYBR Premix Ex TaqTM II (Tli 
RNaseH Plus) were purchased from TaKaRa Bio Ltd. (Da-
lian, China). All other chemicals were of analytical grade. 
MG-63 cells (a human osteosarcoma cell line) and S-180 
cells (a mouse sarcoma cell line) were purchased from the 
Committee of Type Culture Collection of the Chinese 
Academy of Sciences (Shanghai, China). MG-63 cells were 
cultured in Dulbecco’s Minimum Essential Medium 
(DMEM, Gibco, USA) and S-180 cells were grown in 
RPMI1640 Medium (Gibco, USA) supplemented with 10% 
heat-inactivated fetal bovine serum (Gibco, USA) and 1% 
antibiotics (100 U mL1 penicillin and 0.1 mg mL1 strep-
tomycin) (Hyclone, USA). The cells were cultured in a hu-
midified incubator at 37°C (95% humidity, 5% CO2). Kun-
ming mice were purchased from the Slac Laboratory Ani-
mal Co. Ltd. (Shanghai, China). Animals were kept in a 
facility and had free access to food and water, under a 12 h 
light/dark cycle. 
1.2  Cellular level evaluation 
1.2.1  In vitro anti-tumor assay 
The anti-tumor activity of MMCMs against MG-63 cells 
was examined by a cell viability test using the Alamar blue 
proliferation kit. 100 µL of cell suspension was seeded in 
96-well plates (Corning, USA) at a density of 3000 
cells/well and incubated for 24 h to allow cell attachment. 
The culture medium was then replaced by 200 µL of MTX, 
MTX nanoparticles, or MMCMs (C/M) suspension (dis-
persed in DMEM with MTX concentrations of 0.01, 0.1, 1, 
10, and 100 µg mL1) for 72 h. In addition, a time-     
dependent manner survey was performed: cells were incu-
bated with 200 µL of MTX, MTX nanoparticles, MMCMs 
(C/M) (MTX concentrations of 3 µg mL1) or MCMs sus-
pension (blank microspheres, polymer concentration of 100 
µg mL1) for 24, 48, 72, 120, and 168 h. Controls were cul-
tivated under the same conditions with fresh medium. In 
order to negate the effects of medium evaporation, only the 
internal 60 wells were employed for testing and the outer 
wells had 200 µL of PBS added to them. At the determined 
time, assays were implemented according to the manufac-
turer’s instructions. Briefly, the control and test samples 
were removed, and the cells were rinsed twice with PBS, 
then 100 µL of 10% (v/v) Alamar blue solution was added 
to each well. After incubation for 4 h, Alamar blue fluores-
cence was determined at 570 nm, using 600 nm as a refer-
ence wavelength by a microplate reader (Spectra Max M5, 
Molecular Devices, USA). The spectrophotometer was cal-
ibrated to zero absorbance using culture medium without 
cells (blank). Cell viability and half inhibitory concentration 
(IC50, modified Kou-type method) were calculated with the 
following formula:  
Cell viability (%)=[A570600 (sample)A570600 (blank)]/ 
[A570600 (control)A570600 (blank)], 
lgIC50=XmI(P(3PmPn)/4). 
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Here, Xm is lg(maximum dose); I is lg(maximum 
dose/adjacent dose); P represents sum of positive response 
rate; Pm represents the largest positive response rate; Pn 
represents the smallest positive response rate; positive re-
sponse rate=1−cell viability. Data were presented as mean± 
standard deviation (SD) with 6-well repeats. 
1.2.2  Morphological observation 
The morphologies of apoptotic and necrotic cells were de-
tected by AO-EB fluorescence staining. Exponential- 
growth-phase MG-63 cells were seeded at a final concentra-
tion of 1×105/well in 24-well plates and cultured for 24 h, 
after which the culture medium was removed and 1 mL of 
the test sample solutions was added. After 48 h of incuba-
tion, according to the instructions of the normal/apoptotic/ 
necrotic cell detection kit, the cells were harvested with 
0.25% trypsin and re-suspended in 1 mL of DMEM medium. 
After the cells were washed twice with PBS and 
re-suspended in 100 µL of PBS, 25 μL of the cell suspen-
sion was mixed with 1 μL of a mixed dyes reagent for 23 
min in darkness, then 10 µL of samples was placed on a 
microscope slide and visualized under a fluorescence mi-
croscope (Leica, German) using a blue filter. 
1.2.3  Cell cycle assay 
The cell cycles were determined by flow cytometry with PI 
staining according to the cell cycle and apoptosis analysis 
kit. A total of 8×105 MG-63 cells were seeded in 6-well 
plates; after being subcultured for 24 h, the medium was 
changed to an incomplete medium for 12 h for cell cycle 
synchronization, and then the cells were treated with 2 mL 
of the test sample solutions for 48 h. Three dishes with dif-
ferent concentrations were prepared, and then the adhesive 
cells and suspended cells were harvested, pooled, and pel-
leted. After being washed twice with PBS, the cells were 
fixed in ice-cold 70% (v/v) ethanol for 24 h at 4°C. Before 
analysis, the cells were washed with 1 mL of PBS and fil-
tered through a 200 mesh sieve, centrifuged, suspended in 
0.5 mL of staining buffer containing RNase A and PI, and 
then incubated at 37°C for 30 min in darkness. The cells 
were analyzed with a fluorescence excitation wavelength of 
480 nm using a Cell Lab Quanta SC flow cytometer  
(Beckman Coulter). 
1.3  Molecular level evaluation 
1.3.1  Real-time reverse transcription polymerase chain 
reaction (real-time RT-PCR) assay 
The mRNA expressions of bcl-2, bax, and caspase-3 genes 
were detected by real-time RT-PCR. After 1×106 MG-63 
cells were seeded in 6-well plates and incubated for 24 h at 
37°C, the test sample solutions were added to each group, 
with a further incubation for 72 h. The intracellular total 
RNA was extracted with Trizol reagent, and the purity and 
concentration were measured by ultraviolet spectrophotom-
etry; the quality was checked by agarose gel electrophoresis. 
The Prime Script® RT reagent Kit was then used to con-
struct the cDNA library, which was further accessed as the 
template of the real-time PCR. The specific primer and 
β-actin (internal control) sequences (Shanghai Sangone 
Company, China) are listed in Table 1. Real-time PCR reac-
tions were performed using a SYBR Premix Ex TaqTM II 
Kit on the ABI Prism®7500 system. Each reaction was run 
in a 20 µL mixture containing 10 µL of SYBR Premix Ex 
Taq (2×), 0.8 µL of each primer (10 µmol L1), 2 µL of 
cDNA, 0.4 µL of ROX Reference Dye II (50×), and 6 µL of 
ddH2O. A two-step real-time PCR cycle was carried out; the 
steps included an initial predenaturation by heating to 95°C 
for 30 s, followed by 40 cycles involving denaturation at 
95°C for 5 s, and annealing and elongation at 60°C for 34 s. 
The fluorescence signal was harvested at the end of each 
cycle. Melting curve analysis was used to confirm the spec-
ificity of the products. Results were analyzed by the 2CT 
method [29]. 
1.3.2  Western blot assay 
The expression of pro-caspase-3 protein in MG-63 cells was 
detected by Western blot analysis. The cells were first 
treated according to the same procedure described for the 
real time RT-PCR assay, and then the cell lysates were pre-
pared following harvesting of the cells in cell lysis buffer 
for Western blot analysis and IP. The protein was quantified 
by a BCA protein estimation kit, and 100 µg of proteins per 
lane was separated by 12% sodium dodecyl sulfate poly-  
Table 1  Primer sequences for the real-time RT-PCR 













β-actin F305 CTGGGACGACATGGAGAAAA 564 
R868 AAGGAAGGCTGGAAGAGTGC 
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acrylamide gel electrophoresis (SDS-PAGE) and transferred 
electrophoretically to poly(vinylidene fluoride) (PVDF) 
membranes. The membranes were blocked with TBST (100 
mmol L1 Tris-HCl pH 7.5, 150 mmol L1 sodium chloride, 
0.05% Tween-20) containing 5% skimmed milk powder for 
60 min. Then the blots were incubated overnight at 4°C 
with TBST buffer containing appropriate amounts of pri-
mary antibodies: caspase-3 (1:400; Boster, China) and 
β-actin (1:3000; Bioworld Technology, USA). The blots 
were then washed three times with TBST and incubated 
with anti-rabbit secondary antibody conjugated with horse-
radish peroxidase (HRP) (1:1000; Beyotime, China). The 
membranes were washed three times again, and the protein 
signals were detected by an ECL plus kit using an image 
analyzer (Kodak Image Station 4000 MM Pro). Densito-
metric analysis was performed using the Quantity One 
software version 4.6.2. 
1.4  Integrated level evaluation 
1.4.1  In vivo anti-tumor activity 
In vivo anticancer activity against sarcoma-180 (S-180) sol-
id tumors was evaluated in KM mice. Viable S-180 tumor 
cells ((13)×l06) were propagated in the intraperitoneal cav-
ity of adult KM mice by intraperitoneal injection. The S-180 
ascites tumor cells were then harvested on the eighth day 
and suspended at (12)×107 cells mL1 in stroke-     
physiological saline solution; 0.2 mL of this cell suspension 
was inoculated subcutaneously into the right armpit of the 
mice using a 1.0 mL syringe. 
When the tumor volumes reached about 300 mm3 (about 
six days after tumor inoculation), the mice were randomly 
divided into seven groups (six mice/group). Groups 1, 2, 
and 3 were injected with PBS (control), MCMs, and MTX, 
respectively. Groups 45 and 67 were treated with 
MMCMs (C) and MMCMs (M), respectively. For groups 5 
and 7, the tumors were exposed to a 0.4 T magnetic field 
produced by a permanent magnet with the help of adhesive 
tapes immediately after administration [30]. The dose of 
MTX was 10 mg kg1 drug equivalent in all experimental 
mice. Each test compound was administered via tail vein 
injection every other day for 10 d (five times). Body weight 
and tumor volume were measured at defined drug admin-
istration periods, and tumor volume was calculated based on 
the following equation: major axis×(minor axis)2×1/2. 
Twenty-four hours after the last administration, the animals 
were sacrificed by cervical dislocation, and the tumor mass 
was harvested and weighed. The inhibitory rate of the tumor 
was calculated by the following formula: 
 Inhibition ratio (IR, %)=[(A−B)/A]×100%, 
where A is the average tumor weight of the negative control 
and B is that of the treated group. At the end of the experi-
ment, the tumor and small intestine tissues were fixed with 
10% formaldehyde for 24 h and embedded in paraffin. Each 
section was cut to 5 µm, processed for routine hematoxylin 
and eosin (H&E) and Prussian blue staining, and photo-
graphed under an Olympus microscope (BX-51).  
1.4.2  Pharmacokinetics assay 
Pharmacokinetics studies were performed using S-180- 
bearing KM mice models. In total, 84 mice were randomly 
assigned to three groups (28 mice per group): MTX solution, 
MMCMs (M), and MMCMs (M) (with magnetic induction). 
The mice were treated with a single tail vein injection at an 
MTX dose of 10 mg kg1 for each mouse. For the pharma-
cokinetic experiment, at the designated times (5, 15, and 30 
min and 1, 2, 4 and 12 h) after administration, blood sam-
ples were taken from the retro orbital plexus, and plasma 
was isolated by centrifugation (10 min at 3000 r min1) and 
stored at 20°C. The mice were then sacrificed and the ma-
jor tissues, including the tumor and the liver, were collected, 
washed with saline, blotted dry with filter paper, wrapped 
with tinfoil, and stored at 80°C for assay. 
For the plasma sample preparation, 200 µL of the plasma 
sample was added to 100 µL of saline and 100 µL of per-
chloric acid (20%). For the tissue sample preparation, 300 
µL of tissue homogenate was added to 300 µL of perchloric 
acid. The sample mixture was thoroughly vortex-mixed for 
5 min, followed by centrifugation at 10000 r min1 for 10 
min. The supernatant was then centrifuged again, filtered 
through a 0.22 µm filter membrane, and transferred to a 
fresh tube. 20 µL of this solution was injected into the high 
performance liquid chromatography (HPLC) (LC-2000, 
Japan) system for analysis, with experimental conditions as 
follows: C18 column (150 mm×4.6 mm, pore size 5 µm); 
the mobile phase, 3% glacial acetic acid: acetonitrile (90:10, 
v/v); flow rate, 1.0 mL min1; column temperature, 35°C; 
measured wavelength, 303 nm. Non-compartmental phar-
macokinetic analysis was performed using the software 
Winnonlin. The animal experiments were carried out in 
accordance with the guidelines issued by the Ethical Com-
mittee of Huaqiao University. 
1.5  Statistical analysis 
Data were expressed as mean±SD. Results were analyzed 
by one-way ANOVA. P<0.05 was considered statistically 
significant and P<0.01 was considered highly statistically 
significant. 
2  Results and discussion 
2.1  The effect of MMCMs (C/M) on MG-63 cell 
growth in vitro 
Prior to in vivo evaluation, the anti-tumor activity of the 
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MTX formulations at the cellular level was studied by 
means of a colorimetric microculture assay (Alamar blue 
assay), and based on previous reports [31], we chose 
MG-63 cells as the model of cancer cells. The IC50 values of 
MTX, MTX nanoparticles, and MMCMs (C/M) were cal-
culated to be 17.99, 14.03, 6.07, and 8.88 µg mL1, respec-
tively, which suggest that MMCMs (C/M) had an enhanced 
anti-tumor activity compared with raw MTX, showing a 
smaller IC50 than raw MTX. As shown in Figure 1, the cell 
viability of MG-63 cells incubated with MCMs was close to 
100% during the experimental period. It was observed that 
exposure of MG-63 cells to MTX nanoparticles significant-
ly decreased cell viability after four days in comparison 
with exposure to raw MTX over the same period (P<0.01). 
In comparison with the response to raw MTX, the cell via-
bility with MMCMs (C/M) kept decreasing after three days 
(P<0.01); furthermore, values for cell viability with 
MMCMs (M) were the lowest on the seventh day (P<0.01). 
The results indicate that MCMs had almost no effect on cell 
proliferation, and this was consistent with a previous report 
[32]. MTX nanoparticles could induce a lower cell viability 
than raw MTX, which could be explained by the fact that a 
significant increase in the dissolution rate of MTX nanopar-
ticles occurred to increase the bioavailability of MTX [33]. 
Furthermore, compared with MMCMs (C), MMCMs (M) 
had an enhanced anti-cancer efficacy on MG-63 cells in a 
time-dependent manner, which could be attributed to the 
better sustained-release property. The optical micrographs 
of MG-63 cells incubated with different MTX formulations 
were also consistent with this result; it could be seen that 
the attachment ability of the cells incubated with MMCMs 
(C/M) became poor and a large number of cells became 
deformed and brushed off (Figure S1 in Supporting Infor-
mation). 
The results suggest that MMCMs (M) had a better anti-  
 
 
Figure 1  Cell viability of MG-63 cells incubated with 3 µg mL1 of MTX, 
MTX nanoparticles, and MMCMs (C/M), and 100 µg mL1 of MCMs for 1, 
2, 3, 5, and 7 d at 37°C. 
proliferation activity than the other formulations. However, 
the cell viability in the MMCMs (M) group was not signifi-
cantly decreased when compared with previous reports 
[34,35]. This can be explained that the concentration of 
MTX (3 µg mL1) was chosen according to achievable 
plasma drug levels in humans, and it was lower than the 
level of IC50. We believe that the cell viability will be sig-
nificantly decreased when the concentration of MTX is in-
creased with the increasing in drug load of MMCMs (M). 
2.2  The effect of MMCMs (C/M) on MG-63 cell mor-
phology 
AO-EB dual staining is commonly used to study the death 
pattern of cells, distinguishing the viable cells, early/   
medium/late apoptotic cells, and necrotic cells [36]. It is 
known that AO is a cell-permeable dye that intercalates into 
DNA and emits green fluorescence, while EB enters cells 
with disrupted membrane integrity and intercalates into 
RNA and DNA, appearing orange in color. As shown in 
Figure 2, after AO-EB staining, the control cells (A) and 
cells treated with MCMs (B) emitted uniformly green fluo-
rescence and almost no death or apoptosis was observed. In 
contrast, the cells treated with MTX (C) showed the pres-
ence of non-uniform green patches of fragmented and con-
densed chromatin, which are the characteristics of early 
apoptosis. However, some of the cells incubated with the 
MTX nanoparticles (D) and MMCMs (C/M) (E/F) exhibited 
obvious orange patches of fragmented and condensed 
chromatin, nuclear fragmentation, or apoptotic bodies, all of 
which are characteristics of apoptotic programmed cell 
death. Therefore, the above observations demonstrated that 
MMCMs (C/M) could dramatically induce apoptosis of 
MG-63 cells [37], which was also supported by the results 
obtained from the effect of MMCMs (C/M) on MG-63 cell 
growth in vitro. 
2.3  The effect of MMCMs (C/M) on the MG-63 cell 
cycle 
A quantitative evaluation of MMCMs-induced cell death 
was carried out through cell cycle analysis using PI staining, 
which was intended to reflect cell proliferation at various 
stages of cells. PI is a kind of double-stranded DNA fluo-
rescent dye; their combination can produce fluorescence, 
which is detected by flow cytometry, and thus the DNA 
contents are calculated [38]. The effects of different kinds 
of MTX formulations on the cycle of MG-63 cells over 48 h 
are shown in Figure 3, which shows an increase in the S 
phase compared with the control (P<0.01) and also a de-
crease in the G0/G1 phase. It was observed that the S phase 
with 3 µg mL1 of MMCMs (C/M) increased up to 46.83% 
and 48.18%, respectively, while 5.91% in the control. At the 
same time, the G0/G1 phase decreased from 78.29% in the 
control to 36.36% and 34.62%, respectively. There were no 
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Figure 2  AO-EB dual staining of MG-63 cells after culturing with (A) 
fresh medium (control); (B) 100 µg mL1 of MCMs; (C) MTX; (D) MTX 
nanoparticles; (E) MMCMs (C); and (F) MMCMs (M) (with 3 µg mL1 of 
MTX) for 48 h (×400). 
 
Figure 3  Effects of different MTX formulations on the cycle of MG-63 
cells over 48 h. 
significant statistical differences (P>0.05) between the ef-
fects of MTX and MMCMs (C/M) in the S phase, which 
indicated that MMCMs (C/M) did not decrease efficacy and 
arrest the cell cycle in the S phase. As demonstrated by oth-
er published data, MTX is an S phase specific drug, which 
generally produces growth arrest in the S phases of the cell 
cycle [39]. 
2.4  The effect of MMCMs (C/M) on the expression of 
mRNA and protein levels 
The ratio of the pro-apoptotic (bax) to anti-apoptotic (bcl-2) 
molecules is crucial in apoptosis [40]. Inhibition of the ex-
pression of bcl-2 will result in the activation of caspase-3, 
which is a key factor of the Caspase family and plays a very 
important role in cell apoptosis. Therefore, we studied the 
effect of MMCMs (C/M) on bcl-2, bax, and caspase-3 
mRNA and pro-caspase-3 protein expression. The results of 
real-time RT-PCR are shown in Figure 4A and B. The rela-
tive expression levels of bax/bcl-2 and caspase-3 mRNA in 
MTX were higher than those of the other treatments. The 
expression levels of MMCMs (M) were much higher than 
those of MMCMs (C), and the difference was statistically 
significant (P<0.01). The changes in the transcriptional pro-
files of the caspase-3 gene were further reconfirmed by 
Western blot analysis. Potent apoptosis markers such as 
pro-caspase-3 protein were all found to be significantly de-
creased in response to the test chemicals [41]. As shown in 
Figure 5A and B, the pro-caspase-3 protein in the 10 µg 
mL1 of MMCMs (M) was the lowest among all of the for-
mulations. These results demonstrate that MMCMs (M) had 
a pro-apoptotic effect on MG-63 cells, which could effec-
tively increase the gene expression of bax/bcl-2 and caspa-
se-3 and activate the protein expression of pro-caspase-3 
more effectively than MMCMs (C).  
2.5  The effect of MMCMs (C/M) on tumor growth   
in vivo 
To investigate the anti-tumor efficacy of MMCMs (C/M) in 
vivo, we here selected S-180 tumor-bearing mice as an ani-
mal model because it has been one of the classical solid 
tumor models for a long time [42]. Tumor volumes, weights, 
and inhibitory rates were used as evaluating indicators of 
efficacy and are shown in Figure 6 and Table 2. Relative to 
PBS, MCMs resulted in a similar increase in tumor volume 
at all-time points after treatment, with a relatively low IR 
(10%) (P>0.05). However, the other groups showed a tumor 
growth suppression activity. When the mice were treated 
with MTX alone, a mean tumor volume of 1260±180 mm3 
after the last dosing (P<0.01) and a relatively high IR (49%) 
were observed. Under a magnetic field of 0.4 T, MMCMs 
(C) and MMCMs (M) showed mean tumor volumes of 
800±170 (P<0.05) and 560±40 mm3 (P<0.01) after the last 
dosing, respectively, as well as a high IR (54% and 64%, 
respectively). Furthermore, the difference between the ef-
fects of MMCMs (C) and MTX after the last dosing was 
significant (P<0.05), and the difference between the effects 
of MMCMs (M) and MTX (P<0.01) after the last dosing 
was highly significant. This clearly indicates that MMCMs 
(M) under magnetic induction could significantly improve 
the anti-tumor activity of MTX. 
The representative microphotographs of H&E-stained 
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Figure 4  Expression of bax/bcl-2 (A) and caspase-3 (B) mRNA relative expression in MG-63 cells after 72 h of incubation with experimental groups. **, 
P<0.01. 
 
Figure 5  Effects of MTX and MMCMs (C/M) on the activation of pro-caspase-3 in MG-63 cells by Western blots. Proteins were isolated from MG-63 
cells incubated with the control, 10 µg mL1 of MTX, 10 µg mL1 of MMCMs (C), 1 µg mL1 of MMCMs (M), and 10 µg mL1 MMCMs (M) after 72 h. A, 
Expression levels of pro-caspase-3 and β-actin proteins. B, Optical density ratio of pro-caspase-3/β-actin analysis. 
 
Figure 6  The curves of volume change of S-180 solid tumors treated 
with MMCMs. 
sections of S-180 tumor cells are shown in Figure 7. Figure 
7A reveals the presence of typical tumor cells with good 
growth in the S-180 control group (PBS), where the nuclei 
were dyed bright blue by hematoxylin, the cytoplasm was 
dyed in different shades of pink by eosin, and tumor cells 
were dense. However, when the mice were treated with 
MTX and MMCMs (C) subjected to magnetic induction, 
large pink areas and intercellular space can be seen, indi-
cating necrosis (Figure 7B and C) [43]. Furthermore, 
MMCMs (M) under magnetic induction showed more ex-
tensive necrotic areas than the other formulations (Figure 
7D). This was consistent with the results of inhibitory rates. 
Meanwhile, tumor tissues were also observed by Prussian 
blue staining (Figure S2 in Supporting Information). There 
were no blue iron particles in the PBS and MTX groups. 
The MMCMs (C) group showed only small amounts of blue 
iron particles under magnetic induction, while the MMCMs 
(M) group showed a lot of blue iron particles under mag-
netic induction. The above observations also proved that 
MMCMs (M) could considerably improve anti-tumor activ-
ity under magnetic induction. 
The major limitation of cancer chemotherapy is the inju-
ry of normal tissue, leading to multiple organ toxicity. MTX 
is a frequently used cytotoxic agent in the clinic and is as-
sociated with acute and chronic neurotoxicity [44]. In order 
to determine whether MMCMs (C/M) may cause any unde-
sirable side-effects, we assayed the change in body weight 
[45] and H&E staining of normal tissue (small intestine) [46] 
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Figure 7  Histopathological analyses of tumors in S-180 tumor-bearing mice (H&E, ×600). A, Blank control. B, MTX. C and D, MMCMs (C/M) at the 
dose level of 10 mg kg1 under magnetic induction. Thin arrows indicate tumor cells with good growth and thick arrows show tumor necrosis. 
Table 2  Inhibitory rate of S-180 solid tumors treated with MMCMsa) 
Group Tumor weight (g) Inhibitory rate (%) 
S-180 control (PBS) 2.14±0.26 
MCMs 1.92±0.15 10.08 
MTX 1.09±0.18** 49.32 
MMCMs (C) 1.14±0.07** 46.91 
MMCMs (C+magnet) 0.99±0.12** 53.68 
MMCMs (M) 1.14±0.10** 46.83 
MMCMs (M+magnet) 0.77±0.14** 64.21 
a) **, P<0.01. 
as indicators of general toxicity. As presented in Figure 8, 
relative to PBS injected animals, MTX caused a significant 
weight loss by day 7 (P<0.05). Obviously, MMCMs (C) 
with magnetic induction resulted in a highly significant 
weight loss after 7 d (P<0.01). In contrast, the MMCMs (M) 
group under magnetic induction showed a similar increase 
in mean mice weight at all-time points after treatment 
(P>0.05), suggesting that MMCMs (M) were better tolerat-
ed than others. Subsequently, as shown in Figure 9, com-
pared with the control, severe toxicity induced by raw MTX 
was found, such as inflammation. The findings indicated 
that MMCMs (M) were associated with fewer harmful 
side-effects of MTX than MMCMs (C) under magnetic in-
duction. Thus, compared with raw MTX and MMCMs (C), 
MMCMs (M) were demonstrated to be more curative and 
less toxic to the mice. 
 
Figure 8  The weight change of S-180 tumor-bearing mice treated with 
MMCMs.
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Figure 9  Histopathological analyses of the small intestine in S-180 tumor-bearing mice (H&E, ×300). A, Blank control. B, MTX. C and D, MMCMs (C/M) 
at the dose level of 10 mg kg1 under magnetic induction. 
2.6  Pharmacokinetics study 
To further confirm the above results, the pharmacokinetic 
behavior of MMCMs (M) was assessed in S-180 tu-
mor-bearing mice. After intravenous administration of 
MTX solution, MMCMs (C), and MMCMs (M) in the 
presence of a magnetic field, the concentrations of MTX in 
plasma, liver, and tumor were determined by HPLC. The 
concentration versus time profiles of these tissues are shown 
in Figure 10. The corresponding pharmacokinetic parame-
ters in plasma and tissues are listed in Table 3. 
As shown in Figure 10, the MTX concentration had a 
quick decrease after 15 min dosing in the plasma, liver, and 
tumor. MMCMs (M) under magnetic induction displayed a 
longer systemic circulation time, especially in the tumor, 
which suggested a greater in vivo targeted effect. 
As shown in Table 3, for the MTX solution treatment, 
the maximum concentrations (Cmax) in the plasma, liver, and 
tumor were much higher than those of the other treatments. 
By application of the external magnetic field, in the 
MMCMs (M) group, the Cmax increased significantly from 
721 to 979 ng mL1 in the tumor. Furthermore, for time at 
Cmax (Tmax), animals treated with MMCMs (M) under mag-
netic induction exhibited a delayed time to peak concentra-
tion compared with those treated with raw MTX. The ter-
minal phase half-life (t1/2) in plasma with the MTX solution 
treatment was much longer than those with the other treat-
ments. However, under magnetic induction, the t1/2 in the 
tumor was increased up to 1.57-fold compared with 
MMCMs (M) treatment without the magnetic field and 
1.49-fold compared with the MTX solution treatment. The 
mean retention time (MRT) of the MTX solution treatments 
in plasma was longer than those of the other treatments. In 
the tumor, the application of a magnetic field increased the 
MRT up to 2.07-fold compared with MMCMs (M) treat-
ment without the magnetic field and 1.67-fold compared 
with the MTX solution treatment. Administration of 
MMCMs (M) under magnetic induction had the highest 
AUC0−t (area under the MTX concentration-time curve from 
time zero to the last measurable concentration) and AUC0–∞ 
(area under the MTX concentration-time curve from time 
zero to infinity) compared with those of the other treatments 
in plasma and tissues. Furthermore, in the tumor, the 
AUC0−t and AUC0–∞ of the treatment under magnetic in-
duction were increased almost 2.78-fold and 3.63-fold, re-
spectively, compared with treatment without magnetic in-
duction. Comparing systemic clearance (CL) and the vol-
ume of distribution at steady state (Vss) in the plasma and 
tissues, administration of MMCMs (M) under magnetic 
induction significantly decreased the values of CL and Vss 
compared with those of the other treatments. In the tumor, 
administration of MMCMs (M) under magnetic induction 
reduced the CL to 19.3 mL min1 kg1 and the Vss to 12021 
mL kg1, which were lower values than those of the MTX 
solution treatment (50.4 mL min1 kg1 and 18863 mL kg1, 
respectively) and the MMCMs (M) treatment without mag- 
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Figure 10  Plasma (A) and tissue (liver (B), tumor (C)) concentration-time curves after intravenous administration of MTX solution and MMCMs 
(M/M+magnet). The values are expressed as mean±SD (n=4). 
Table 3  Pharmacokinetic parameters of MTX in mice plasma and tissues after intravenous administration of MTX solution and MMCMs (M/M+magnet) 











h ng mL1 
AUC0∞ 
h ng mL1 
CL 




MTX 6973 0.083 4.84 3.50 7214 7952 21.0 4405 
MMCMs (M) 1825 0.083 1.55 2.17 3951 3968 42.0 5467 
MMCMs 
(M+magnet) 
3018 0.500 2.38 2.88 9715 10072 16.5 2862 
Liver 
MTX 9671 0.083 4.35 5.60 22072 26114 6.38 2146 
MMCMs (M) 6453 0.250 6.02 7.67 20763 26980 6.18 2842 
MMCMs 
(M+magnet) 
8875 0.500 3.98 4.78 33713 37893 4.40 1261 
Tumor 
MTX 1415 0.250 4.74 6.24 2696 3307 50.4 18863 
MMCMs (M) 721 0.500 4.49 5.02 2063 2372 70.3 21164 
MMCMs 
(M+magnet) 
979 0.500 7.08 10.40 5735 8615 19.3 12021 
a) Cmax, maximum concentration; Tmax, time at Cmax; t1/2, terminal phase half-life; MRT, mean retention time; AUC0−t, area under the MTX concentra-
tion-time curve from time zero to the last measurable concentration; AUC0–∞, area under the MTX concentration-time curve from time zero to infinity; CL, 
systemic clearance; Vss, the volume of distribution at steady state. 
netic induction (70.3 mL min1 kg1 and 21164 mL kg1, 
respectively). 
Zhu et al. [47] developed MTX-loaded thermosensitive 
magnetoliposomes, when these liposomes were intrave-
nously administrated in rats, 3.85-fold increase of Cmax and 
9.68-fold increase of MTX accumulation (AUC0−t) in skele-
tal muscle compared with the absence of magnet were ob-
served. Similar phenomena were also found in our study, 
the pharmacokinetic behaviors of MTX had a marked dif-
ference among the free MTX solution, MMCMs (M) and 
MMCMs (M) in the presence of magnetic field. MMCMs 
(M) under magnetic induction increased Cmax in 1.36-fold 
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and AUC0−t in 2.78-fold compared with the absence of 
magnet, and 2.0-fold increase of Tmax and 2.13-fold increase 
of AUC0−t compared with free MTX.  
The increase in Cmax indicated that the nanoparticles were 
effective in increasing the drug absorption, and the delayed 
Tmax demonstrated an obvious sustained release of MTX. 
This was probably because that MMCMs (M) had a good 
magnetic response and sustained-release effect. Overall, 
under magnetic induction, MMCMs (M) showed the great-
est accumulation of MTX in tumor tissues compared with 
the other formulations, resulting in an increase in the thera-
peutic index and safety profile of MTX. 
3  Conclusion 
To use the MMCMs (C/M) in a drug delivery system, we 
evaluated their biological effectiveness by measuring their 
in vitro and in vivo anti-tumor effects. The anti-tumor effi-
cacy in MG-63 cells was enhanced by MMCMs (M), which 
have an effective long-term anti-tumor effect and induce 
cell cycle arrest in vitro. In addition, MMCMs (M) in-
creased the gene expression of bax/bcl-2 and caspase-3 and 
activated the protein expression of pro-caspase-3 more ef-
fectively than MMCMs (C). Moreover, MMCMs (M) sig-
nificantly decreased tumor growth and showed a lower tox-
icity in vivo. The pharmacokinetics study showed that the 
MTX Cmax, Tmax, t1/2, and AUC were significantly increased 
by MMCMs (M) under magnetic induction, while distribu-
tion and clearance were decreased, indicating a prolonged 
circulation time and an increased bioavailability. Based on 
our present data, MMCMs (M) show great potential for use 
in the magnetic targeted therapy field. 
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Supporting Information 
Figure S1  Optical micrographs of MG-63 cells cultured for 72 h (×100) with fresh medium (control) (A); 100 µg mL1 MCMs (B); 3 µg mL1 MTX (C);  
3 µg mL1 MTX nanoparticles (D); 3 µg mL1 MMCMs (C) (E); 3 µg mL1 MMCMs (M) (F). 
Figure S2  Prussian blue staining of tumor in S-180 bearing mice (×300): (A) blank control; (B) MTX; (C and D) MMCMs (C/M) at the dose level of   
10 mg kg1 under magnetic induction. 
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